Short Interest in MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) Drops By 25.4%

MAIA Biotechnology, Inc. (NYSEAMERICAN:MAIA) was the recipient of a significant decline in short interest in March. As of March 15th, there was short interest totalling 708,700 shares, a decline of 25.4% from the February 28th total of 950,600 shares. Based on an average trading volume of 278,000 shares, the short-interest ratio is currently 2.5 days. Currently, 3.3% of the company’s shares are short sold.

MAIA Biotechnology Price Performance

Shares of MAIA stock opened at $1.62 on Friday. MAIA Biotechnology has a 12-month low of $1.46 and a 12-month high of $5.99. The stock’s fifty day moving average is $1.84. The company has a market capitalization of $42.38 million, a P/E ratio of -1.17 and a beta of 0.20.

Institutional Trading of MAIA Biotechnology

Several hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new position in shares of MAIA Biotechnology during the 3rd quarter worth approximately $31,000. Jane Street Group LLC acquired a new position in MAIA Biotechnology during the fourth quarter worth $77,000. Finally, Geode Capital Management LLC grew its position in MAIA Biotechnology by 22.9% in the third quarter. Geode Capital Management LLC now owns 192,563 shares of the company’s stock valued at $541,000 after purchasing an additional 35,821 shares in the last quarter. Institutional investors and hedge funds own 5.65% of the company’s stock.

About MAIA Biotechnology

MAIA Biotechnology, Inc, a clinical stage biotechnology company, engages in the discovery, development, and commercialization of therapies targeting cancer. The company's lead product candidate is THIO, a telomere-targeting agent that is in Phase II clinical study to evaluate its activity in patients with non-small cell lung cancer.